Concourse Financial Group Securities, Inc. Aligos Therapeutics, Inc. Call Options Transaction History
Concourse Financial Group Securities, Inc.
- $1.64 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALGS
# of Institutions
42Shares Held
45.7MCall Options Held
1.4KPut Options Held
300-
Armistice Capital, LLC New York, NY7.26MShares$73.9 Million0.03% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.39MShares$65.1 Million0.08% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.1MShares$62.2 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5MShares$51 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$36.1 Million0.18% of portfolio
About Aligos Therapeutics, Inc.
- Ticker ALGS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,717,000
- Market Cap $405M
- Description
- Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...